This document outlines details of PBS-subsidised blinatumomab, dasatinib, imatinib, inotuzumab and ponatinib for patients with acute lymphoblastic leukaemia (ALL).
For information on how to process a PBS Authority see Processing Complex Authority Required Listings. Contact a Local Peer Support (LPS) if unsure of how to action an application.
On this page:
Blinatumomab, dasatinib, imatinib, inotuzumab and ponatinib applications
Blinatumomab quick reference
Dasatinib quick reference
Imatinib quick reference
Inotuzumab ozogamicin quick reference
Ponatinib quick reference
Blinatumomab, dasatinib, imatinib, inotuzumab and ponatinib applications
Table 1
|
Step |
Action |
|
1 |
Dasatinib and imatinib and ‘first line’ applications
There is a lifetime maximum of 24 months of continuing treatment.
The patient may switch between ‘first line’ dasatinib or imatinib treatment due to toxicity or intolerance.
|
|
2 |
Blinatumomab only applications
-
Induction treatment is limited to a maximum of 2 treatment cycles in a patient’s lifetime
-
Consolidation treatment is limited to
-
a maximum of 3 treatment cycles in a patient’s lifetime for relapsed or refractory, or
-
two treatment cycles in a patient's lifetime for measurable residual disease
-
The Online PBS Authorities system will reject applications for treatment beyond the maximum allowed. If the prescriber needs a top up or replacement the assessment may need to be overridden
|
|
3 |
Inotuzumab applications
-
Induction treatment is limited to a maximum of 3 treatment cycles in a patient’s lifetime
-
Consolidation treatment is limited to a maximum of 5 treatment cycles in a patient’s lifetime
-
Patients are limited to a maximum of 6 total treatment cycles in a lifetime across the induction and consolidation treatment restrictions
|
Blinatumomab quick reference
Table 2
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
|
Initial (Induction)
PB210 form
|
Written - S100 |
No |
OPA |
N/A |
No |
|
Continuing (Consolidation) |
Telephone/Electronic - S100 |
No |
OPA |
N/A |
Yes |
|
Induction - Balance of Supply |
Telephone/Electronic – S100 |
No |
OPA |
N/A |
Yes |
Dasatinib quick reference
Table 3
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
|
Initial – first line
PB271 form
|
Written - S85 |
Yes |
OPA |
N/A
|
No |
|
Initial – second line
PB077 form
|
Written – S85 |
Yes |
OPA |
N/A |
No |
|
Continuing |
Telephone/Electronic - S85 |
No |
OPA |
N/A |
Yes |
|
Change – whilst in first line initial phase (due to toxicity)
|
Written – S85 |
Yes |
OPA |
N/A |
No |
|
Change – whilst in first line continuing phase (due to toxicity)
|
Telephone/Electronic – S85 |
No |
OPA |
N/A |
Yes |
Imatinib quick reference
Table 4
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
|
Initial |
Telephone - S85 |
No |
OPA |
N/A |
No |
|
Continuing |
Streamlined - S85 |
No |
N/A |
N/A |
Yes |
|
Change – whilst in first line initial phase (due to toxicity) |
Telephone /Electronic – S85 |
No |
OPA |
N/A |
Yes |
|
Change – whilst in first line continuing phase (due to toxicity) |
Streamlined – S85 |
No |
N/A |
N/A |
Yes |
Inotuzumab ozogamicin quick reference
Table 5
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
|
Initial (Induction)
PB269 form
|
Written - S100 EFC |
Yes |
OPA |
N/A |
No |
|
Continuing (Consolidation)
|
Telephone/Electronic - S100 EFC |
No |
OPA |
N/A |
Yes |
Ponatinib quick reference
Table 6:
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
|
Initial
PB169 form
|
Written - S85 |
Yes |
OPA |
N/A |
No |
|
Continuing |
Telephone/Electronic - S85 |
No |
OPA |
N/A
|
Yes |
Expand all